Human Matriptase/ST14 Catalytic Domain Antibody Summary
Val615-Val855
Accession # Q9Y5Y6
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Matriptase/ST14 in PC‑3 Human Cell Line by Flow Cytometry. PC-3 human prostate cancer cell line was stained with Mouse Anti-Human Matriptase/ST14 Catalytic Domain Monoclonal Antibody (Catalog # MAB3946, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed with paraformaldehyde and permeabilized with saponin.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Matriptase/ST14
Human Matriptase, encoded by the ST14 (suppression of tumorogenicity 14) gene, is also known as tumor associated differentially expressed gene 15 protein/TADG‑15), epithin, and membrane-type serine protease 1/MT-SP1 (1). Predicted to have a significant role in tumor biology, Matriptase may be a novel target for anti-cancer therapy (2). However, expressed in most human epithelia, Matriptase is also important in several physiological processes (1). For example, it activates prostasin to initiate a protease cascade that is essential for epidermal differentiation (3), and it converts a single-chain IGFBP-rp1 into the two-chain form (4). Matriptase is a type II transmembrane serine protease with a complex modular structure (1). The 855 amino acid (aa) sequence of human Matriptase consists of a cytoplasmic tail (aa 1‑55), a transmembrane domain (aa 56‑76), and an extracellular portion (aa 77‑855). The latter contains the following domains: SEA (aa 86‑201), two CUBs (aa 214‑334 and 340‑447), four LDLRAs (aa 452‑486, 487‑523, 524‑560, and 566‑603), and a serine protease (aa 615‑855). The physiological activation of the single-chain zymogen requires the cleavage at the SEA domain within the ER or Golgi, association with HAI-1, which facilitates the transport of the protease to the cell surface, and auto-cleavage at QAR-V(615)VGG (1). The activated Matriptase is inhibited by HAI-1, and the resulting HAI-1 complex can be shed from the cell surface (1).
- List, K. et al. (2006) Mol. Med. 12:1.
- Uhland, K. (2006) Cell. Mol. Life Sci. 63:2968.
- Netzel-Arnett, S. et al. (2006) J. Biol. Chem. 281:32941.
- Ahmed, S. et al. (2006) FEBS J. 273:615.
Product Datasheets
Citations for Human Matriptase/ST14 Catalytic Domain Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
4
Citations: Showing 1 - 4
Filter your results:
Filter by:
-
Downregulation of matriptase suppresses the PAR?2/PLCgamma2/PKC?mediated invasion and migration abilities of MCF?7 breast cancer cells
Authors: JM Kim, J Park, EM Noh, HK Song, SY Kang, SH Jung, JS Kim, HJ Youn, YR Lee
Oncology reports, 2021-10-05;46(6):.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.
Authors: Hwang S, Kim H, Min M, Raghunathan R, Panova I, Munshi R, Ryu B
J Invest Dermatol, 2015-04-24;135(9):2283-91.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot -
Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
Authors: Zoratti G, Tanabe L, Varela F, Murray A, Bergum C, Colombo E, Lang J, Molinolo A, Leduc R, Marsault E, Boerner J, List K
Nat Commun, 2015-04-15;6(0):6776.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Proteolytic cleavage of human acid-sensing ion channel 1 by the serine protease matriptase.
Authors: Clark EB, Jovov B, Rooj AK
J. Biol. Chem., 2010-07-02;285(35):27130-43.
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot
FAQs
-
Why is intracellular flow staining performed with Human Matriptase/ST14 Catalytic Domain Antibody (Catalog #s MAB3946 and AF3946) when Human Matripase is a type II transmembrane serine protease?
We have performed intracellular staining with Catalog #s MAB3946 and AF3946 because when PC-3 and some other cell lines were tested using the surface staining protocol, the results were negative. It is possible that the level of expression of this protein is too low to be detected on the surface. Furthermore, with optimization of staining, one may be able to detect protein on the surface.
Reviews for Human Matriptase/ST14 Catalytic Domain Antibody
There are currently no reviews for this product. Be the first to review Human Matriptase/ST14 Catalytic Domain Antibody and earn rewards!
Have you used Human Matriptase/ST14 Catalytic Domain Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
